189 related articles for article (PubMed ID: 37317963)
1. RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia.
Ren JG; Xing B; Lv K; O'Keefe RA; Wu M; Wang R; Bauer KM; Ghazaryan A; Burslem GM; Zhang J; O'Connell RM; Pillai V; Hexner EO; Philips MR; Tong W
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37317963
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms for regulation of RAS palmitoylation and plasma membrane trafficking in hematopoietic malignancies.
Yu F; Qian Z
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37317974
[TBL] [Abstract][Full Text] [Related]
3. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
4. Palmitoylation of oncogenic NRAS is essential for leukemogenesis.
Cuiffo B; Ren R
Blood; 2010 Apr; 115(17):3598-605. PubMed ID: 20200357
[TBL] [Abstract][Full Text] [Related]
5. GOLGA7 is essential for NRAS trafficking from the Golgi to the plasma membrane but not for its palmitoylation.
Liu C; Jiao B; Wang P; Zhang B; Gao J; Li D; Xie X; Yao Y; Yan L; Qin Z; Liu P; Ren R
Cell Commun Signal; 2024 Feb; 22(1):98. PubMed ID: 38317235
[TBL] [Abstract][Full Text] [Related]
6. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
[TBL] [Abstract][Full Text] [Related]
7. Artemisinin inhibits NRas palmitoylation by targeting the protein acyltransferase ZDHHC6.
Qiu N; Abegg D; Guidi M; Gilmore K; Seeberger PH; Adibekian A
Cell Chem Biol; 2022 Mar; 29(3):530-537.e7. PubMed ID: 34358442
[TBL] [Abstract][Full Text] [Related]
8. Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A.
Zhao H; Liu P; Zhang R; Wu M; Li D; Zhao X; Zhang C; Jiao B; Chen B; Chen Z; Ren R
J Hematol Oncol; 2015 Dec; 8():132. PubMed ID: 26715448
[TBL] [Abstract][Full Text] [Related]
9. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
[TBL] [Abstract][Full Text] [Related]
11. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice.
Zambetti NA; Firestone AJ; Remsberg JR; Huang BJ; Wong JC; Long AM; Predovic M; Suciu RM; Inguva A; Kogan SC; Haigis KM; Cravatt BF; Shannon K
Blood; 2020 May; 135(20):1772-1782. PubMed ID: 32219446
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NRAS Signaling in Melanoma through Direct Depalmitoylation Using Amphiphilic Nucleophiles.
Vora HD; Johnson M; Brea RJ; Rudd AK; Devaraj NK
ACS Chem Biol; 2020 Aug; 15(8):2079-2086. PubMed ID: 32568509
[TBL] [Abstract][Full Text] [Related]
13. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
Rajagopalan A; Feng Y; Gayatri MB; Ranheim EA; Klungness T; Matson DR; Lee MH; Jung MM; Zhou Y; Gao X; Nadiminti KV; Yang DT; Tran VL; Padron E; Miyamoto S; Bresnick EH; Zhang J
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37847561
[TBL] [Abstract][Full Text] [Related]
14. MEK1 is required for the development of NRAS-driven leukemia.
Nowacka JD; Baumgartner C; Pelorosso C; Roth M; Zuber J; Baccarini M
Oncotarget; 2016 Dec; 7(49):80113-80130. PubMed ID: 27741509
[TBL] [Abstract][Full Text] [Related]
15. Ras palmitoylation is necessary for N-Ras activation and signal propagation in growth factor signalling.
Song SP; Hennig A; Schubert K; Markwart R; Schmidt P; Prior IA; Böhmer FD; Rubio I
Biochem J; 2013 Sep; 454(2):323-32. PubMed ID: 23758196
[TBL] [Abstract][Full Text] [Related]
16. NRAS is unique among RAS proteins in requiring ICMT for trafficking to the plasma membrane.
Ahearn IM; Court HR; Siddiqui F; Abankwa D; Philips MR
Life Sci Alliance; 2021 May; 4(5):. PubMed ID: 33579760
[TBL] [Abstract][Full Text] [Related]
17. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.
Morgan MA; Dolp O; Reuter CW
Blood; 2001 Mar; 97(6):1823-34. PubMed ID: 11238126
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
[TBL] [Abstract][Full Text] [Related]
19. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
20. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
